1) Buckley PF:Efficacy of quetiapine for the treatment of schizophrenia:A combined analysis of three placebo-controlled trials. Curr Med Res Opin 20:1357-1363, 2004
2) Kasper S, Brecher M, Fitton L, et al:Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol 19:281-289, 2004
3) Kondo T, Otani K, Ishida M, et al:Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 16:120-124, 1994
4) Mintzer JE, Mullen JA, Sweitzer DE:A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin 20:1483-1491, 2004
5) 岡田正範,更井啓介,児玉宣久,他:二重盲検法によるZotepineとTiotixeneの精神分裂病に対する薬効比較.精神医学 22:947-965,1980
6) Petit M, Raniwalla J, Tweed J, et al:A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia:A parallel-group double-blind trial. Psychopharmacol Bull 32:81-87, 1996
7) Tauscher J, Kufferle B, Asenbaum S, et al:Striatal dopamine-2 receptor occupancy as measured with[123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology(Berl) 162:42-49, 2002